Ignite Creation Date:
2024-05-06 @ 2:02 AM
Last Modification Date:
2024-10-26 @ 11:13 AM
Study NCT ID:
NCT01959815
Status:
COMPLETED
Last Update Posted:
2021-11-15
First Post:
2013-10-08
Brief Title:
Novel Screening Strategies for Scleroderma PAH
Sponsor:
University of Michigan
Organization:
University of Michigan
Study Overview
Official Title:
Novel Screening Strategies for Scleroderma PAH Pulmonary Arterial Hypertension
Status:
COMPLETED
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with scleroderma can develop heart failure due to high blood pressure in the lungs a condition called pulmonary arterial hypertension It is important to find pulmonary arterial hypertension early so that it can be treated before heart failure develops However the tests that we now use to find the earliest form of this disease in scleroderma patients are not good enough This study will examine whether tests performed during exercise can improve our ability to find early pulmonary arterial hypertension The study will also try to identify genes that are responsible for the development of pulmonary arterial hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None